Sun Pharmaceutical Industries reported a drop in second-quarter profit on Friday, dragged by a one-time charge related to its acquisition of Organon.
Consolidated net profit fell to ₹1,989 crore ($209.31 million) in the quarter ended September 30 from ₹3,118 crore a year earlier.
The drugmaker booked a one-time charge of ₹1,269 crore, largely comprising acquisition-related costs for its planned purchase of Organon, along with provisions linked to India’s new labour code framework.
($1 = 95.0250 Indian rupees)
Published on October 30, 2026
